Otsuka Holdings Past Earnings Performance
Past criteria checks 1/6
Otsuka Holdings has been growing earnings at an average annual rate of 1.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 10.5% per year. Otsuka Holdings's return on equity is 6.1%, and it has net margins of 6.7%.
Key information
1.4%
Earnings growth rate
1.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 10.5% |
| Return on equity | 6.1% |
| Net Margin | 6.7% |
| Next Earnings Update | 14 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Otsuka Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,269,564 | 151,575 | 923,851 | 312,313 |
| 30 Jun 24 | 2,179,961 | 126,817 | 888,794 | 309,650 |
| 31 Mar 24 | 2,089,741 | 137,563 | 845,547 | 312,223 |
| 31 Dec 23 | 2,018,568 | 121,616 | 807,355 | 307,804 |
| 30 Sep 23 | 1,950,959 | 184,702 | 777,521 | 297,102 |
| 30 Jun 23 | 1,871,228 | 166,860 | 757,007 | 292,125 |
| 31 Mar 23 | 1,806,034 | 172,194 | 745,187 | 283,851 |
| 31 Dec 22 | 1,737,998 | 133,906 | 724,129 | 275,230 |
| 30 Sep 22 | 1,656,978 | 109,845 | 706,655 | 263,543 |
| 30 Jun 22 | 1,593,768 | 103,809 | 678,679 | 254,588 |
| 31 Mar 22 | 1,541,795 | 104,036 | 642,606 | 243,043 |
| 31 Dec 21 | 1,498,276 | 125,463 | 622,326 | 232,299 |
| 30 Sep 21 | 1,463,284 | 147,019 | 596,462 | 221,303 |
| 30 Jun 21 | 1,446,198 | 152,734 | 579,099 | 210,550 |
| 31 Mar 21 | 1,420,055 | 155,109 | 562,954 | 211,122 |
| 31 Dec 20 | 1,422,826 | 148,137 | 562,434 | 216,841 |
| 30 Sep 20 | 1,434,441 | 143,398 | 560,802 | 219,909 |
| 30 Jun 20 | 1,420,552 | 146,198 | 558,797 | 224,980 |
| 31 Mar 20 | 1,421,844 | 145,709 | 563,043 | 219,069 |
| 31 Dec 19 | 1,396,240 | 127,151 | 557,607 | 215,789 |
| 30 Sep 19 | 1,372,665 | 116,333 | 562,504 | 211,273 |
| 30 Jun 19 | 1,344,787 | 86,379 | 567,319 | 220,080 |
| 31 Mar 19 | 1,311,287 | 78,918 | 571,343 | 224,569 |
| 31 Dec 18 | 1,291,981 | 82,492 | 564,374 | 216,140 |
| 30 Sep 18 | 1,269,004 | 117,106 | 551,893 | 212,434 |
| 30 Jun 18 | 1,262,916 | 133,942 | 544,768 | 190,872 |
| 31 Mar 18 | 1,254,410 | 114,206 | 557,945 | 181,513 |
| 31 Dec 17 | 1,239,952 | 112,492 | 558,677 | 175,558 |
| 30 Sep 17 | 1,211,772 | 75,029 | 565,791 | 185,597 |
| 30 Jun 17 | 1,196,154 | 88,267 | 557,511 | 177,785 |
| 31 Mar 17 | 1,193,159 | 94,933 | 535,629 | 169,451 |
| 31 Dec 16 | 1,195,547 | 92,563 | 535,852 | 168,818 |
| 30 Sep 16 | 1,240,874 | 71,521 | 504,554 | 164,309 |
| 30 Jun 16 | 1,294,177 | 61,301 | 532,243 | 177,728 |
| 31 Mar 16 | 1,342,728 | 68,735 | 546,741 | 192,335 |
| 31 Dec 15 | 1,445,227 | 84,053 | 597,350 | 201,010 |
| 31 Dec 14 | 1,599,424 | 151,237 | 630,029 | 255,907 |
| 30 Sep 14 | 1,541,631 | 163,443 | 602,577 | 246,447 |
| 30 Jun 14 | 1,515,577 | 156,499 | 577,133 | 247,685 |
| 31 Mar 14 | 1,452,759 | 150,956 | 542,805 | 249,010 |
| 31 Dec 13 | 1,403,125 | 174,046 | 491,656 | 241,922 |
Quality Earnings: OS1 has a large one-off loss of ¥236.9B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: OS1's current net profit margins (6.7%) are lower than last year (9.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OS1's earnings have grown by 1.4% per year over the past 5 years.
Accelerating Growth: OS1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: OS1 had negative earnings growth (-17.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.4%).
Return on Equity
High ROE: OS1's Return on Equity (6.1%) is considered low.